Aviva PLC Sells 200,187 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Aviva PLC reduced its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN – Get Rating) by 76.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 61,174 shares of the company’s stock after selling 200,187 shares during the quarter. Aviva PLC’s holdings in Elanco Animal Health were worth $748,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. HBK Sorce Advisory LLC bought a new stake in Elanco Animal Health during the fourth quarter worth $183,000. EverSource Wealth Advisors LLC increased its holdings in shares of Elanco Animal Health by 381.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 4,229 shares of the company’s stock valued at $52,000 after purchasing an additional 3,350 shares during the last quarter. Skylands Capital LLC increased its holdings in shares of Elanco Animal Health by 20.9% in the fourth quarter. Skylands Capital LLC now owns 208,450 shares of the company’s stock valued at $2,547,000 after purchasing an additional 36,000 shares during the last quarter. Treasurer of the State of North Carolina increased its holdings in shares of Elanco Animal Health by 1.3% in the fourth quarter. Treasurer of the State of North Carolina now owns 193,287 shares of the company’s stock valued at $2,362,000 after purchasing an additional 2,460 shares during the last quarter. Finally, Prudential PLC acquired a new position in shares of Elanco Animal Health in the fourth quarter valued at $356,000.

Analyst Ratings Changes

Several research firms have commented on ELAN. Morgan Stanley decreased their price objective on shares of Elanco Animal Health from $20.00 to $19.00 and set an “equal weight” rating on the stock in a report on Monday, January 30th. Barclays upgraded shares of Elanco Animal Health from an “equal weight” rating to an “overweight” rating and set a $14.00 price objective on the stock in a report on Thursday, April 20th. Finally, Piper Sandler decreased their price objective on shares of Elanco Animal Health from $15.00 to $12.00 in a report on Thursday, March 2nd. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, Elanco Animal Health currently has a consensus rating of “Hold” and an average price target of $16.50.

Elanco Animal Health Trading Down 2.2 %

ELAN stock opened at $8.51 on Monday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.24 and a current ratio of 2.25. The company’s 50-day simple moving average is $9.20 and its 200 day simple moving average is $11.36. Elanco Animal Health Incorporated has a 52 week low of $8.48 and a 52 week high of $24.93. The company has a market capitalization of $4.19 billion, a PE ratio of -212.70, a price-to-earnings-growth ratio of 6.14 and a beta of 0.92.

Elanco Animal Health (NYSE:ELAN – Get Rating) last released its quarterly earnings results on Tuesday, May 9th. The company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.29 by $0.16. Elanco Animal Health had a negative net margin of 0.49% and a positive return on equity of 8.21%. The business had revenue of $1.26 billion for the quarter, compared to the consensus estimate of $1.18 billion. During the same period in the prior year, the company posted $0.36 earnings per share. Elanco Animal Health’s revenue was up 2.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Elanco Animal Health Incorporated will post 0.8 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director R David Hoover acquired 10,000 shares of Elanco Animal Health stock in a transaction on Friday, March 3rd. The shares were purchased at an average cost of $11.13 per share, for a total transaction of $111,300.00. Following the completion of the purchase, the director now directly owns 155,000 shares of the company’s stock, valued at approximately $1,725,150. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other news, CEO Jeffrey N. Simmons acquired 15,000 shares of Elanco Animal Health stock in a transaction on Friday, March 10th. The shares were purchased at an average cost of $9.60 per share, for a total transaction of $144,000.00. Following the completion of the purchase, the chief executive officer now directly owns 45,000 shares of the company’s stock, valued at approximately $432,000. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director R David Hoover acquired 10,000 shares of Elanco Animal Health stock in a transaction on Friday, March 3rd. The shares were purchased at an average price of $11.13 per share, for a total transaction of $111,300.00. Following the completion of the purchase, the director now directly owns 155,000 shares of the company’s stock, valued at $1,725,150. The disclosure for this purchase can be found here. Corporate insiders own 6.40% of the company’s stock.

Elanco Animal Health Profile

(Get Rating)

Elanco Animal Health, Inc innovates, develops, manufactures, and markets products for pets and farm animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine.